Together with normalized serum AST and ALT levels (Table 2), these findings indicate that inhibitions of resistin expression and secretion with RNA oligo can improve HFD-induced pathological changes in NAFLD. This evidence concerns the gene GPT and metabolic dysfunction-associated steatotic liver disease.